How long can you live with multiple myeloma without treatment?

Survival without treatment for multiple myeloma depends almost entirely on what stage the disease has reached when someone asks the question. A person diagnosed with smoldering myeloma, a precursor state that has not yet caused organ damage, may live for a decade or longer without any therapy. A person with active, symptomatic myeloma who receives no treatment faces a much shorter timeline, historically measured in months rather than years. The enormous gap between those two realities makes the question genuinely complicated, and the answer requires understanding where a person falls on the spectrum between early, quiet disease and full-blown cancer.

The Precursor States That Can Persist for Years

Multiple myeloma almost always develops through a series of earlier conditions that are detectable but do not cause symptoms. The first is called monoclonal gammopathy of undetermined significance, or MGUS. If you are told you have MGUS, you do not have cancer. Your body is making an abnormal protein, but the cells producing it are not yet causing harm. The risk of MGUS progressing to myeloma or a related condition is roughly one percent per year, and many people with MGUS live out their entire lives without ever developing cancer.¹ There is no treatment for MGUS itself, only monitoring, so living with it “without treatment” is the standard medical approach.

The next step along the spectrum is smoldering multiple myeloma. Here the abnormal plasma cells have multiplied further, and the abnormal protein level is higher, but the disease still has not damaged organs. In a study that followed 276 smoldering myeloma patients over 26 years, about 10 percent per year progressed to active myeloma during the first five years, roughly three percent per year for the next five years, and about one percent per year after that. By 15 years, the cumulative probability of progressing to active disease was 73 percent.² That means roughly a quarter of smoldering myeloma patients had still not progressed after a decade and a half. For these people, the disease behaved more like a chronic condition than a fatal cancer.

The practical takeaway is that if your question is about surviving without treatment and your diagnosis is MGUS or low-risk smoldering myeloma, the honest answer is that many people do so for many years. The biology of these precursor states is genuinely different from active myeloma, and watchful waiting has long been the default recommendation for both.

Active Myeloma Without Treatment

Once myeloma crosses the line into active disease, meaning it starts damaging bones, kidneys, or blood cell production, the picture changes sharply. Before modern chemotherapy became available in the 1960s, the median survival for symptomatic myeloma was roughly six to twelve months. Even after early drugs extended that timeline, untreated active myeloma remained lethal on a relatively short horizon because the disease attacks several organ systems simultaneously.

The reason untreated active myeloma is so dangerous is not just that cancer cells are growing. The cancer disrupts the body’s basic machinery in multiple ways at once, and any one of those disruptions can become fatal on its own. Understanding these complications explains why survival without treatment is measured in months rather than years for most people with symptomatic disease.

How Untreated Myeloma Damages the Body

Myeloma cells crowd out normal blood-producing cells in the bone marrow, leading to anemia. Research has shown that more than 80 percent of newly diagnosed myeloma patients are anemic, and more than 60 percent have moderate or severe anemia at the time they are first diagnosed.³ The myeloma cells do not simply take up space; they actively interfere with the production of red blood cells by disrupting the specialized structures where those cells develop and by releasing chemicals that cause red blood cell precursors to die off prematurely.⁴ Without treatment, anemia worsens progressively, causing fatigue, breathlessness, and eventually heart strain.

Bone destruction is another hallmark. Myeloma cells stimulate the cells that break down bone while simultaneously suppressing the cells that rebuild it, leading to lytic lesions, fractures, and severe pain. This bone loss also releases calcium into the bloodstream, creating hypercalcemia, the most common metabolic crisis in myeloma. Depending on how high calcium levels climb, hypercalcemia can cause confusion, kidney damage, heart rhythm problems, and death if untreated.⁵ In roughly five percent of myeloma patients, a vertebral fracture leads to spinal cord compression, which can cause paralysis if not addressed promptly.⁶

The kidneys are vulnerable because the abnormal proteins produced by myeloma cells can clog the tiny filtering structures inside the kidney, a condition called cast nephropathy. This is the leading cause of acute kidney injury in myeloma patients.⁷ Once kidney function declines significantly, the body loses its ability to clear waste products and regulate fluid balance, compounding every other problem the disease creates.

Infection is perhaps the most immediate threat. Myeloma suppresses the immune system by crowding out the normal plasma cells that produce protective antibodies. Research on newly diagnosed patients found that those with significant immune suppression had infection rates above 50 percent, compared to about 16 percent in patients without immune suppression. In statistical terms, partial or full immune suppression increased the risk of early infection by roughly eight- to ninefold.⁸ Without treatment to control the cancer and without supportive antibiotics or immunoglobulin replacement, infections become recurrent and increasingly difficult to survive.

Why the Timeline Varies So Much Between Patients

Not all myeloma behaves the same way. The genetic makeup of the cancer cells, the speed at which they multiply, and how much damage they have already caused at diagnosis all influence how long someone can survive. Some people have relatively slow-growing disease with a single bone lesion and mild anemia. Others present with kidney failure, multiple fractures, and dangerously high calcium on the same day they are diagnosed. The first patient might live for years even with minimal intervention; the second might not survive weeks without emergency care.

At the extreme aggressive end of the spectrum sits plasma cell leukemia, where myeloma cells spill out of the bone marrow and circulate in the bloodstream. Secondary plasma cell leukemia, which develops in someone who already has myeloma, carries a median survival of only about three months, even with treatment. Primary plasma cell leukemia, diagnosed in someone who never had prior myeloma, has a median survival of roughly 37 months with treatment, but drops to about 12 or 13 months without a transplant.⁹ These numbers illustrate how dramatically biology can shorten the timeline. Without any treatment at all, secondary plasma cell leukemia would likely be fatal within weeks.

On the opposite end, rare cases of remarkably indolent myeloma exist. One published case described a patient who survived 20 years after a myeloma diagnosis while receiving essentially no systemic anti-myeloma therapy for the first 18 of those years, despite having features that would normally be considered high risk.¹⁰ Cases like this are genuinely exceptional and should not be used to set expectations, but they demonstrate that the biology of myeloma is not uniform. Some tumors simply grow much more slowly than others, for reasons that are not always predictable at diagnosis.

What Happens When Diagnosis Is Delayed

Many people effectively live with undiagnosed, untreated myeloma for months before anyone figures out what is going on. Myeloma’s early symptoms, including back pain, fatigue, and recurrent infections, overlap with dozens of more common conditions, so diagnostic delays are unfortunately common. A study of diagnostic timing found that patients whose symptoms lasted longer before diagnosis were significantly more likely to have multiple complications at the time they were finally diagnosed. Among those with symptoms for less than three months, 40 percent had no complications at all, while every patient in the most delayed group had two or more complications.¹¹

Interestingly, the same study found that a longer time to diagnosis had a significant negative effect on disease-free survival but not on overall survival. That may seem counterintuitive, but it suggests that while delayed diagnosis allows more complications to accumulate, the underlying biology of the cancer still drives the long-term outcome once treatment begins. The practical implication for someone worried about untreated myeloma is that the damage done during the untreated period can be lasting, particularly to kidneys and bones, even if eventual treatment extends life.

The Growing Debate Over Treating Smoldering Myeloma Early

For decades, the standard approach to smoldering myeloma was to watch and wait, only starting treatment when the disease progressed to active myeloma. That consensus has been shifting. A meta-analysis of five randomized trials involving 844 patients with intermediate- or high-risk smoldering myeloma found that early treatment reduced the risk of disease progression or death by about 60 percent compared to observation alone.¹²

Three large randomized trials have now met their primary endpoints favoring early intervention, with one demonstrating an overall survival benefit and another showing a trend toward one.¹³ This matters for the “how long without treatment” question because it means that at least some people who would historically have been told to wait are now being offered therapy that could delay or even prevent the transition to active disease.

The picture is not entirely straightforward, though. A systematic review of 45 smoldering myeloma trials found that most used progression-free survival rather than overall survival as their primary endpoint, and when the same drug regimens were tested in both smoldering and active myeloma, they generally produced lower response rates in the smoldering group.¹⁴ Smoldering myeloma cells do not always behave the same way as active myeloma cells, which means that delaying progression does not automatically guarantee that people live longer overall. For low-risk smoldering myeloma, observation remains reasonable. For high-risk smoldering disease, the evidence increasingly favors starting treatment before complications develop.

Living Longer Without Curative Treatment

Even for people who cannot or choose not to receive full anti-myeloma therapy, supportive care can meaningfully extend survival and improve quality of life. Bisphosphonates, drugs that slow bone destruction, have been studied extensively in myeloma. A network meta-analysis of 14 randomized trials found moderate-quality evidence that bisphosphonates may reduce mortality, with the most potent version, zoledronate, showing a survival benefit.¹⁵ Bisphosphonates are not chemotherapy; they target the bone disease itself, reducing fractures and potentially keeping calcium levels in check.

Palliative and supportive care programs that address the full range of myeloma symptoms have shown real benefits. Tailored interventions focusing on energy management, nutritional support, and pain control can improve fatigue, appetite, and overall quality of life in myeloma patients. Multidisciplinary approaches combining physical therapy, psychological support, and careful pain management have proven particularly effective for the bone pain and exhaustion that dominate myeloma patients’ daily experience.¹⁶

These interventions do not cure the disease, but they can make the difference between someone spending their remaining time bedbound and someone maintaining some degree of independence. For older patients or those with other serious health conditions who decide against aggressive chemotherapy, supportive care is not giving up; it is a different strategy for managing a disease that will be present regardless.

When the Question Really Means Something Else

People searching for how long they can live with myeloma without treatment are often asking one of several more specific questions. Some have been told they have smoldering myeloma and want to know if they truly need to start chemotherapy right now. The answer, for many, is not yet, though the definition of “high risk” smoldering myeloma continues to expand as early treatment trials report positive results. Others have active myeloma and are weighing whether the side effects of treatment are worth the survival benefit. For active disease, the gap between treated and untreated survival is large enough that treatment is almost always recommended if the person can tolerate it.

A third group may be asking because they or a loved one has run out of treatment options after multiple relapses. At that point, the question shifts from untreated natural history to end-of-life trajectory, and the answer depends on which organ systems are most affected and how quickly the disease is growing. In this context, good palliative care and honest conversations with an oncologist about prognosis become more valuable than any statistic about average survival times.

The Immune System After Myeloma Takes Hold

One aspect of living with untreated myeloma that deserves specific attention is the progressive collapse of normal immune function. Myeloma is, at its core, a cancer of the immune system’s antibody-producing cells. As the malignant plasma cells multiply, they suppress the production of normal immunoglobulins, the proteins that fight off bacteria and viruses. This immunodeficiency is not a theoretical concern. The research on immunoparesis in newly diagnosed patients showed that even partial immune suppression, where just one or two classes of immunoglobulins were reduced, was enough to increase infection risk dramatically compared to patients with intact immune function.⁸

Without treatment, immunoparesis only deepens over time. Patients become vulnerable not just to unusual infections but to common ones: pneumonia, urinary tract infections, and skin infections can become life-threatening. Before modern antibiotics and supportive care, infection was the leading cause of death in myeloma patients. Even today, it remains a major contributor to mortality. For someone living with untreated myeloma, practical infection-avoidance measures like vaccination, prompt antibiotic use for any sign of infection, and avoiding crowded environments during cold and flu season can make a tangible difference in how long they survive and how well they feel during that time.

The immune dysfunction also explains why myeloma patients sometimes develop a second unrelated cancer. The surveillance function of the immune system, which normally identifies and destroys abnormal cells before they can form tumors, is compromised along with the antibody-producing function. This is a long-term risk that becomes more relevant for people with slower-growing disease who survive for many years, particularly those in the smoldering myeloma or MGUS categories who may live long enough for a separate cancer to emerge through other mechanisms entirely.